Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronar...(ion of insulin-like growth factor-I (IGF...)

Date:3/11/2008

ion of insulin-like growth factor-I (IGF-I) following a single intracoronary administration in an acute care setting after percutaneous coronary intervention to restore blood flow in heart attack patients. Numerous studies have shown that ongoing damage to cells within the infarct zone continues to occur even after blood flow has been restored, a phenomenon known as reperfusion injury. Corgentin is intended to enhance myocardial healing in and around the infarct zone when used as an adjunct to existing pharmacologic and interventional therapies. Results of the study indicate that non-surgical intracoronary infusion of an adenovector carrying a reporter gene to the heart enables robust protein expression in the area of the myocardium at risk due to ischemia and reperfusion injury. The recently completed preclinical development study follows an earlier pilot study using a similar myocardial infarct model in which intracoronary administration of Ad5IGF-I was found to preserve heart tissue and function following an acute myocardial infarction.

"These positive preclinical results confirm that our intracoronary infusion approach can be used to successfully deliver therapeutic adenovectors into acutely ischemic myocardium such as occurs after a heart attack, at very high efficiency, without the need for any needle injections into the myocardium. Confirmation that non-surgical adenovector delivery through a standard catheter such as those used routinely for angiography can effectively target the acutely diseased heart substantially advances our Corgentin development program," stated Christopher J. Reinhard, Chairman and CEO of Cardium. "The highly effective delivery to acutely ischemic myocardium following intracoronary infusion extends the findings of high first pass uptake of Generx in the hearts of patients with chronic ischemia as observed in the AGENT-1 clinical study, and underscores the potential of these approaches to be applied to the treatment of various fo
'/>"/>

SOURCE Cardium Therapeutics, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. Genmab Announces Encouraging Preclinical Data for ofatumumab
2. Arius Features Preclinical Data on Antibody Candidates at Two Conferences
3. Preclinical Research on Coronary Stent with CeloNova BioSciences Polyzene(R)- F Nanocoating Receives Award at CIRSE 2007
4. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
5. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
6. Arpida Presents Preclinical Data on AR-2474 at ICAAC
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. Genta Announces Presentation of New Clinical and Preclinical Data on Genasense(R) at AACR-NCI-EORTC Targets Conference
9. ANX-514 Reduces Hypersensitivity Reactions Without Impacting Pharmacokinetics or Antitumor Activity in Preclinical Tests
10. Preclinical Efficacy Data Demonstrate Ability of Tengions Neo-Bladder Augment to Restore Bladder Function
11. GelVac(TM) Nasal Powder H5N1 (Bird Flu) Influenza Vaccine Passes Preclinical Toxicology Studies